Laddar...
Docetaxel for the Treatment of Hormone-Refractory Prostate Cancer
Chemotherapy has historically proven toxic and ineffective for the treatment of metastatic hormone-refractory prostate cancer (HRPC), a disease with substantial morbidity and mortality. Progress has been made in symptom relief, and the combination of mitoxantrone and prednisone is considered the pal...
Sparad:
| Huvudupphovsman: | |
|---|---|
| Materialtyp: | Artigo |
| Språk: | Inglês |
| Publicerad: |
MedReviews, LLC
2003
|
| Ämnen: | |
| Länkar: | https://ncbi.nlm.nih.gov/pmc/articles/PMC1502348/ https://ncbi.nlm.nih.gov/pubmed/16985945 |
| Taggar: |
Lägg till en tagg
Inga taggar, Lägg till första taggen!
|